Webinar preview: Valio spots potential of exosomes in infant nutrition innovations – nutritioninsight.com

Report on Innovations in Infant Nutrition and Sustainable Development

Introduction

Valio is advancing research into the application of exosomes for infant nutrition. The primary objective is to develop infant formula with a composition that more closely mimics human breast milk. Exosomes, which are nanosized vesicles generated by cells, function as critical messengers in cellular communication and are integral to early-life development. In human milk, they are key mediators that support an infant’s gut maturation, immune function, and nervous system development. This report outlines the potential of this research, its associated challenges, and its significant contributions to the United Nations Sustainable Development Goals (SDGs).

Contribution to Sustainable Development Goals (SDGs)

The development of advanced infant formula through exosome research directly supports several key SDGs aimed at improving global health and well-being.

SDG 2: Zero Hunger

This initiative contributes to Target 2.2, which aims to end all forms of malnutrition. By enhancing the nutritional quality of infant formula, this research helps ensure that infants who are not breastfed receive nourishment that better supports healthy growth and development.

• Improving formula to be compositionally closer to breast milk provides superior nutrition, combating potential deficiencies.
• The inclusion of bioactive components like exosomes supports foundational aspects of infant health, preventing malnutrition from the earliest stage of life.

SDG 3: Good Health and Well-being

The research aligns with Target 3.2, focused on ending preventable deaths of newborns and children under five. Enhanced infant nutrition is a cornerstone of early childhood health.

• Exosomes in breast milk are known to regulate gene expression, which directly influences gut maturation and immune responses.
• The proteins and lipids within exosomes provide antimicrobial defense and immune modulation.
• Exosomes facilitate communication between neurons, supporting brain development and the establishment of neural connections.

SDG 9: Industry, Innovation, and Infrastructure

The effort to incorporate exosomes into commercial infant formula represents a significant technological innovation within the food industry. It pushes the boundaries of milk science and manufacturing processes.

• The research focuses on developing novel methods to isolate and preserve the bioactivity of exosomes.
• It drives innovation in milk fractionation and formula production to handle these delicate nanovesicles.
• This work represents a new frontier, as current infant formulas contain negligible amounts of active exosomes.

Technical Challenges and Collaborative Solutions

Processing and Bioactivity Hurdles

A primary challenge is the preservation of exosome integrity and activity during the manufacturing of infant milk formula. Standard industrial processes pose a significant threat to these vesicles.

1. Processing steps such as pasteurization and homogenization can lead to the degradation or reduced activity of exosomes.
2. A key technical goal is to develop methods for isolating exosomes from milk early in the process and reintroducing them into the final formula.
3. Bovine milk exosomes differ in composition from human milk exosomes, presenting a challenge in mimicking the specific functionality required for infant development.

SDG 17: Partnerships for the Goals

To overcome these challenges, strategic collaboration is essential. The partnership between Valio, an industry leader, and the University of Oulu exemplifies the multi-stakeholder approach advocated for in SDG 17.

• This collaboration combines Valio’s expertise in cow’s milk fractionation and infant formula manufacturing with the university’s deep academic understanding of exosomes.
• The partnership aims to develop the technologies necessary to make exosomes a standard, natural component of commercial infant formulas.

Conclusion and Future Directions

The research into milk exosomes is a critical step toward advancing infant nutrition. By striving to replicate the unique functionality of human milk, this work holds the potential to significantly improve health outcomes for infants globally. The successful integration of exosomes into infant formula will not only represent a major scientific achievement but also a tangible contribution to achieving the Sustainable Development Goals related to health, nutrition, and innovation.

Analysis of SDGs, Targets, and Indicators

1. Which SDGs are addressed or connected to the issues highlighted in the article?

The article on Valio’s research into exosomes for infant nutrition connects to several Sustainable Development Goals (SDGs), primarily focusing on health, nutrition, and innovation.

• SDG 2: Zero Hunger: This goal aims to end hunger, achieve food security and improved nutrition. The article’s focus on enhancing the nutritional quality of infant formula to be closer to breast milk directly addresses the “improved nutrition” aspect, particularly for infants who are not breastfed.
• SDG 3: Good Health and Well-being: This goal seeks to ensure healthy lives and promote well-being for all at all ages. The research discussed aims to improve infant health outcomes by supporting gut maturation, immune function, and nervous system development, which are critical for a healthy start in life.
• SDG 9: Industry, Innovation, and Infrastructure: This goal encourages building resilient infrastructure, promoting inclusive and sustainable industrialization, and fostering innovation. The article highlights Valio’s investment in scientific research, development of new technologies for milk processing, and innovation in infant formula manufacturing.
• SDG 17: Partnerships for the Goals: This goal emphasizes the need for global partnerships to achieve the SDGs. The article explicitly mentions the collaboration between Valio (industry) and the University of Oulu (academia) as crucial for advancing the research and development of new infant formulas.

2. What specific targets under those SDGs can be identified based on the article’s content?

Based on the article’s content, the following specific targets can be identified:

• Target 2.2: By 2030, end all forms of malnutrition, including achieving, by 2025, the internationally agreed targets on stunting and wasting in children under 5 years of age, and address the nutritional needs of adolescent girls, pregnant and lactating women and older persons.
  • Explanation: The article’s central theme is the effort to “make formulas as close as possible to breast milk” by incorporating exosomes. This directly contributes to improving the nutritional quality of infant formula, which is a key strategy in combating malnutrition in infants who rely on it.
• Target 3.2: By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births.
  • Explanation: While the article does not mention mortality rates, it details how exosomes support “gut maturation, immune responses,” “antimicrobial defense,” and “brain development.” Improving these fundamental aspects of infant health through better nutrition is a direct pathway to reducing infant morbidity and, consequently, preventable deaths.
• Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending.
  • Explanation: The article is a clear example of this target in action. It describes Valio’s advanced scientific research into exosomes, the challenge of developing “methods to isolate exosomes from milk,” and the overall goal to “inspire innovations in infant formula.” This represents a direct investment in R&D to upgrade technological capabilities in the food industry.
• Target 17.17: Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.
  • Explanation: The article explicitly highlights the “academic-industry collaboration, like Valio’s work with the University of Oulu.” This partnership is presented as essential to combine “deep academic understanding of exosomes with Valio’s expertise in cow’s milk fractionation and infant formula manufacturing” to achieve the desired innovation.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

The article implies several indicators that could be used to measure progress, even if official UN indicators are not explicitly named.

• For Target 2.2 (End Malnutrition):
  • Implied Indicator: The compositional quality of infant formula. Progress could be measured by the concentration and bioactivity of key components like exosomes in commercial formulas compared to the gold standard of human breast milk. The article states that “currently infant formulas contain negligible amounts of exosomes,” providing a baseline for measurement.
• For Target 3.2 (Reduce Child Mortality):
  • Implied Indicator: Infant health and development outcomes. Progress could be measured through clinical studies tracking improvements in “gut maturation,” “immune function,” and “nervous system development” in infants fed the new formula. These are proxy indicators for overall health and resilience against diseases that cause mortality.
• For Target 9.5 (Enhance Scientific Research and Innovation):
  • Implied Indicator: Investment in food science R&D and development of new technologies. Progress can be measured by the amount of private funding allocated to research projects like Valio’s, the number of patents filed for new processing techniques (e.g., “methods to isolate exosomes… and reintroduce them”), and the launch of new, scientifically advanced products.
• For Target 17.17 (Promote Partnerships):
  • Implied Indicator: The number and effectiveness of academic-industry collaborations in the food and nutrition sector. The success of the partnership between Valio and the University of Oulu, measured by research outputs and the successful development of “commercial infant formulas” with exosomes, serves as a direct indicator of this target.

Summary Table of SDGs, Targets, and Indicators

Source: nutritioninsight.com